Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
Thistle Resources intersects broad gold mineralization at Middle River
06:01am, Wednesday, 10'th Jun 2026
Thistle Resources (TSX-V:TRCG, OTC:TRCGF) has intersected broad, high-grade gold mineralization at its Middle River Gold Project, the company said...
Snail Games brings Bellwright to PlayStation and Xbox as console push advances
05:46am, Wednesday, 10'th Jun 2026
Snail Inc (NASDAQ:SNAL) has launched its open-world kingdom-building survival RPG Bellwright on PlayStation and Xbox, extending a title that has surpassed...
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share
05:36am, Wednesday, 10'th Jun 2026
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has agreed to be acquired by privately held Kuva Labs Inc. for $4 per share in cash, plus a contingent value...
Abacus Global Management launches AI lifespan modeling platform
04:41am, Wednesday, 10'th Jun 2026
Abacus Global Management (NYSE:ABX) has unveiled LifeARC, a proprietary AI-powered platform that generates personalized lifespan models for individuals...
After shedding its cancer business just over a decade ago, GSK's new CEO is building back with a $10.6 billion deal
09:00pm, Tuesday, 09'th Jun 2026
After shedding its oncology business just over a decade ago, GSK is building it back with a $10.6 billion deal.
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
04:36pm, Tuesday, 09'th Jun 2026
Gilead and Merck report positive phase III results for once-weekly HIV regimen islatravir/lenacapavir, while ending a lung cancer study.
GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout
01:16pm, Tuesday, 09'th Jun 2026
GSK buys Nuvalent for $10.6 billion, adding three lung cancer pipeline candidates and expanding its precision oncology presence.
GSK Acquires Nuvalent for $10.6 Billion to Enhance Cancer Pipeline
12:14pm, Tuesday, 09'th Jun 2026
GSK (GSK) is experiencing a modest uptick in its stock price following the announcement of its acquisition of Nuvalent (NUVL) for $124 per share, totaling $10.6
Tuesday's Morning Movers: MU Rebounds, ON PT Increases & GSK Buys NUVL
10:30am, Tuesday, 09'th Jun 2026
Diane King Hall discusses this morning's top moving stocks by highlighting Micron (MU) as it rallies back after Friday's sell-off. She also touches on Wells Fargo raising its ON Semiconductor's (ON) p
5 Things to Know Before the Stock Market Opens
09:31am, Tuesday, 09'th Jun 2026
Stock futures are pointing to a higher open Tuesday as the market looks to extend its recovery from last week's losses; President Trump said last night that the U.S. and Iran are close to a "very, ver
Nuvalent Catapults To Record High On GSK's $10.6 Billion All-Cash Bid
09:21am, Tuesday, 09'th Jun 2026
Nuvalent shares catapulted to a record high Tuesday after GSK made an all-cash bid to buy the small biotech company for $10.6 billion.
Nuvalent Stock Soars on $10.6 Billion GSK Buyout
09:12am, Tuesday, 09'th Jun 2026
Nuvalent Inc (NASDAQ:NUVL) is soaring in premarket trading, up 38.9% to trade at $122.88, after London-based GSK agreed to acquire the cancer drug developer in an all-cash deal valued at approximately
GSK Agrees $10.6 Billion Nuvalent Deal at 40% Premium
08:20am, Tuesday, 09'th Jun 2026
GSK (GSK) has agreed to acquire Nuvalent Inc. (NUVL) in a $10.6 billion cash deal, giving the British pharmaceutical company a bigger foothold in precision onco
Breakfast News: CRM & ACN Lead Wave Of M&A Action
07:30am, Tuesday, 09'th Jun 2026
Multiple notable acquisitions hit the market, OpenAI submits IPO documents, and more
GSK's $10.6B Nuvalent takeover fails to impress investors as shares fall: here's why
07:02am, Tuesday, 09'th Jun 2026
GlaxoSmithKline is making its largest oncology acquisition in years with a $10.6 billion deal for US-based cancer drug developer Nuvalent, betting that a trio of promising lung cancer therapies can he
